Why the study?
Recent advances in understanding AF pathophysiology and atrial remodeling highlighted opportunities for new therapeutic approaches, despite unmet needs and limited drug development in the field.
This review highlights the stagnation in new antiarrhythmic drug development for atrial fibrillation and emphasizes the future role of personalized medicine.
Answers are grounded in this paper and cite their sources.
Highlights emerging AF drug targets; leaves open clinical validation of novel agents.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Casado-Arroyo et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: